ImmunoCellular Therapeutics, Ltd.
(NYSE Amex Equities : IMUC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Loading IMUC News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.76%172.501.1%$711.75m
GILDGilead Sciences, Inc.
0.09%70.540.9%$695.99m
CELGCelgene Corporation
0.47%134.311.1%$649.60m
REGNRegeneron Pharmaceuticals, Inc.
-1.75%517.332.7%$572.31m
ALXNAlexion Pharmaceuticals, Inc.
-0.13%126.071.9%$521.18m
BIIBBiogen Inc.
-0.09%280.321.2%$500.23m
VRTXVertex Pharmaceuticals Incorporated
-1.50%133.501.9%$279.31m
INCYIncyte Corporation
0.48%136.282.6%$278.87m
CLVSClovis Oncology, Inc.
-1.84%95.0018.0%$249.90m
TSROTESARO, Inc.
-2.16%146.5314.7%$249.01m
ILMNIllumina, Inc.
1.25%185.283.5%$164.61m
BLUEBluebird Bio, Inc.
-5.49%112.0019.3%$162.00m
PBYIPuma Biotechnology, Inc.
1.22%87.5021.1%$145.68m
KITEKite Pharma, Inc.
7.09%100.6616.1%$139.56m
EXASExact Sciences Corporation
2.31%35.5126.3%$130.55m

Company Profile

ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. Its lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 31, 2006 and is headquartered in Calabasas, CA.,0087QL-E